Feasibility of REHIT in NDH Patients

July 6, 2019 updated by: Matthew Haines, University of Huddersfield

Feasibility of Procedures for a Pragmatic Randomized Controlled Trial of Reduced Exertion, High-intensity Interval Training (REHIT) With Non-diabetic Hyperglycaemia Patients

The aim of this feasibility study was to describe and report data relevant to the acceptability of an exercise intervention (reduced-exertion, high-intensity interval training) in non-diabetic hyperglycaemia patients delivered in a National Health Service setting.

Study Overview

Status

Completed

Detailed Description

Background Physical activity and exercise interventions to improve health frequently bring about intended effects under ideal circumstances but fail to demonstrate effectiveness when translated to demonstrable benefits in real-world contexts. The aim of this feasibility study was to describe and report data relevant to the acceptability of an exercise intervention (reduced-exertion, high-intensity interval training) in non-diabetic hyperglycaemia (NDH) patients delivered in a National Health Service (NHS) setting.

Individuals with NDH are an intermediary group of patients whose blood glucose levels are higher than normal but not high enough to be diagnosed as diabetic. Such hyperglycaemic blood glucose excursions in 'pre-diabetic' states contribute to the development of macro- and micro-vascular disease risk and increases the risk of developing overt type 2 diabetes. Interventions - such as increased physical activity - for individuals who are diagnostically considered to have NDH are high priority, as they provide a substantial opportunity for preventing future burden of diabetes on patients, the NHS, and the economy.

Evidence supporting the efficacy of exercise and physical activity as preventative or therapeutic treatments for a range of chronic diseases, including obesity and diabetes, is incontrovertible. However, exercise adherence is considered a significant issue. The most commonly cited barrier to undertaking physical activity is perceived 'lack of time'. Consequently, there has been a recent interest in high-intensity interval training (HIT) which is characterised by brief periods of repeated very high-intensity exercise interspersed with longer periods of recovery. More recently attempts have been made to modify HIT to make it more time-efficient and tolerable. This approach is known as reduced-exertion, high-intensity interval training (REHIT). In this study, issues of acceptability and feasibility were considered when implementing a REHIT intervention into usual care within an NHS setting.

Methods The purpose was to assess whether it would be appropriate to progress to a larger-scale pragmatic trial, and to optimise the design and conduct of any such trial. The intention was to recruit 40 participants from a single centre (specialist diabesity centre). Patients were eligible to take part if they were diagnostically defined as non-diabetic hyperglycaemic based on a glycated haemoglobin value of 42-46 mmol·mol. Methodological issues were used to analyse problems that arose.

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Accessing the NHS Trust Weight Management Service (Specialist Diabesity Clinic)
  • Aged between 18 and 65 years (inclusive)
  • Diagnosed as NDH (using standard criteria)
  • Male or female
  • Any ethnicity
  • Not currently partaking in a new structured exercise intervention
  • Considered low or medium risk for exercise using standard risk stratification [37]

Exclusion Criteria:

  • < 18 years and ≥ 66 years
  • Currently partaking in a new structured exercise intervention
  • Euglycaemic
  • Diagnosed with type 1 or type 2 diabetes; taking insulin; history of end stage liver or kidney disease, neuropathy or retinopathy; has hypertension that cannot be controlled by standard medication; has cardiovascular disease, or another contraindication to exercise
  • Considered high risk for exercise using standard risk stratification [37]
  • Unable to adequately understand verbal explanations and written information given in English (there were no funds available for translation services)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Exercise intervention (reduced-exertion, high-intensity interval training) alongside normal treatment. [low recruitment prohibited control arm]
Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients screened and considered eligible to take part in the study
Time Frame: 4-weeks
Defined as the number of patients who had contact with the recruitment team and who were assessed for eligibility using inclusion and exclusion criteria.
4-weeks
Reporting of adverse events
Time Frame: From first exposure to intervention to last (approx. 6-weeks)
An adverse event was defined as any untoward occurrence that happened during the conduct of the study.
From first exposure to intervention to last (approx. 6-weeks)
Intervention adherence
Time Frame: From first exposure to intervention to last (approx. 6-weeks)
Intervention adherence was calculated by summing the total number of participants and the target number of REHIT sessions (15 per participant) and comparing this against the actual completed sessions.
From first exposure to intervention to last (approx. 6-weeks)
Change in affective valence (pleasure-displeasure)
Time Frame: Change from first exposure to intervention to last (approx. 6 weeks)
Pre-validated 'Feeling Scale' questionnaire which measure pleasure/displeasure responses during exercise. This is a single-item, 11-point, bipolar scale and ranges from - 5 'very bad' to + 5 'very good', with anchors designated for 0 (neutral) and all odd integers in-between. Lower scores are considered to be a worse outcome.
Change from first exposure to intervention to last (approx. 6 weeks)
Change in perceived exertion
Time Frame: Change from first exposure to intervention to last (approx. 6 weeks)
Pre-validated 'Rating of Perceived Exertion' questionnaire which measures perceived effort during exercise. This is a 15-point scale and ranges from 6 'no exertion' to 20 'maximal exertion' with anchors designated for all the odd integers in-between. A higher score is considered a worse outcome.
Change from first exposure to intervention to last (approx. 6 weeks)
Change in enjoyment
Time Frame: Change from first exposure to intervention to last (approx. 6 weeks)
Pre-validated 'Exercise Enjoyment Scale' (ESS) which measures enjoyment associated with exercise. This is a single-item, 7-point scale. Anchors are given at every integer, ranging from 1 'not at all' to 7 'extremely'. A lower score is a worse outcome.
Change from first exposure to intervention to last (approx. 6 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in peak oxygen uptake (fitness test)
Time Frame: Change from baseline peak oxygen uptake at approx. 6-weeks
Progressive cycle test to measure cardiovascular fitness (using gas analysis)
Change from baseline peak oxygen uptake at approx. 6-weeks
Change in HBA1c (blood test)
Time Frame: Change from baseline HbA1c at approx. 6-weeks
Widely used measure of blood glucose control
Change from baseline HbA1c at approx. 6-weeks
Change in body composition
Time Frame: Change from baseline body composition at approx. 6-weeks
Fat mass and fat-free mass estimated via bioelectrical impedance analysis
Change from baseline body composition at approx. 6-weeks
Change in systolic and diastolic blood pressure
Time Frame: Change from baseline systolic and diastolic blood pressure at approx. 6-weeks
Measured via automated digital blood pressure monitor
Change from baseline systolic and diastolic blood pressure at approx. 6-weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Matthew Haines, University of Huddersfield

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2016

Primary Completion (Actual)

January 1, 2017

Study Completion (Actual)

January 1, 2017

Study Registration Dates

First Submitted

June 26, 2019

First Submitted That Met QC Criteria

July 4, 2019

First Posted (Actual)

July 8, 2019

Study Record Updates

Last Update Posted (Actual)

July 9, 2019

Last Update Submitted That Met QC Criteria

July 6, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • UHuddersfield

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

Clinical Trials on Exercise intervention

Subscribe